Appendix 4E and Annual Report 30 June 2026

Summary by 6ix AI

The report indicates a slight decline in revenues and a significant increase in losses compared to the previous year. No dividends were declared during the reporting period, and the company is focusing on advancing its clinical trials and product commercialization strategies. The report also highlights ongoing challenges in patient recruitment for trials and plans for regulatory approvals to expand market access.

Written by 6ix AI from the company’s filing. How 6ix writes summaries